Maxalt Rpd

Rizatriptan, the active ingredient in Maxalt Rpd, is a Triptan presented as a tablet for oral use. It is prescribed for the acute treatment of migraine attacks in adults, helping to alleviate headache pain and associated symptoms.

GNH USA supplies Maxalt Rpd as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for healthcare providers across multiple regions. Our distribution network ensures timely delivery and compliance with local regulatory requirements.

Rizatriptan is a selective serotonin 5‑HT1B/1D receptor agonist used in the migraine therapeutic pathway.

Migraine with aura: provides rapid relief of headache pain and associated symptoms. Migraine without aura: reduces the intensity and duration of migraine attacks. Acute migraine attacks: helps abort the migraine episode when taken at onset.

Rizatriptan may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Chest discomfort: mild pressure or tightness in the chest. - Tingling sensations: numbness or paresthesia in the face or extremities. - Dizziness: feeling light‑headed or unsteady. - Nausea: mild stomach upset or urge to vomit.

Serious or Rare Side Effects: - Serotonin syndrome: potentially life‑threatening condition with agitation, fever, and muscle rigidity. - Cardiac events: severe chest pain, arrhythmias, or myocardial infarction.

When prescribing Rizatriptan, clinicians should consider several precautionary measures to ensure safe use. - Cardiovascular assessment: evaluate history of coronary artery disease, angina, or uncontrolled hypertension before use. - Concomitant serotonergic drugs: avoid combining with other serotonergic agents to reduce risk of serotonin syndrome. - Age considerations: use with caution in patients over 65 years due to increased sensitivity to vascular effects. - Pregnancy and lactation: assess risk‑benefit ratio; limited data are available, so use only if clearly needed. - Driving and machinery: advise patients that dizziness may impair ability to operate vehicles or equipment. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Rizatriptan can interact with other medications, affecting its efficacy or safety profile.

Major Interactions (Avoid): - MAO‑A inhibitors: risk of severe hypertension and serotonin syndrome. - Other triptans or ergotamine derivatives: increased vasoconstrictive effects leading to cardiovascular complications. - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): elevate rizatriptan plasma levels, raising toxicity risk.

Moderate Interactions (Monitor Closely): - SSRIs, SNRIs, and other serotonergic antidepressants: monitor for signs of serotonin syndrome. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce rizatriptan effectiveness. - Antihypertensive agents: possible additive blood pressure lowering effects.